Arcutis Biotherapeutics, Inc.
ARQT
$31.19
$1.234.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 7.41M | -15.89M | -25.06M | -10.79M | -41.54M |
| Total Depreciation and Amortization | 562.00K | 410.00K | 3.13M | 458.00K | 1.27M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.22M | 10.67M | 9.24M | 11.15M | 9.38M |
| Change in Net Operating Assets | -19.94M | 5.13M | -17.69M | -1.57M | -3.80M |
| Cash from Operations | -1.75M | 324.00K | -30.38M | -748.00K | -34.69M |
| Capital Expenditure | 0.00 | -78.00K | -608.00K | 0.00 | -143.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -25.25M | 17.50M | 12.36M | 34.88M | 84.92M |
| Cash from Investing | -25.25M | 17.42M | 11.75M | 34.88M | 84.78M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -100.00M | -- |
| Issuance of Common Stock | 1.48M | 1.38M | 395.00K | 2.59M | 394.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.48M | 1.38M | 395.00K | -97.41M | 394.00K |
| Foreign Exchange rate Adjustments | -95.00K | 200.00K | 4.00K | -234.00K | 98.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -25.62M | 19.33M | -18.23M | -63.52M | 50.58M |